Glucose-dependent insulin secretion (GSIS)

Glucose-dependent insulin secretion" is not a single molecule, protein, receptor, enzyme, or gene, but rather describes the physiological mechanism by which pancreatic β-cells sense increases in blood glucose and respond by secreting insulin. This tightly regulated pathway involves several key molecular players: * When blood glucose rises after eating, glucose enters pancreatic β-cells via GLUT2 transporters[4][6]. * Inside the cell, glucokinase phosphorylates glucose to glucose-6-phosphate—this is considered the rate-limiting step and makes glucokinase the primary "glucose sensor" for these cells[2][3][4]. * Metabolism of glucose through glycolysis and mitochondrial oxidation increases intracellular ATP/ADP ratio[1][7]. * The rise in ATP closes ATP-sensitive potassium channels (KATP), leading to membrane depolarization[1][5]. * Depolarization opens voltage-gated calcium channels; calcium influx triggers exocytosis of insulin-containing vesicles into circulation[3]. This mechanism ensures that insulin is secreted only when needed—that is, when blood sugar levels are elevated. Disruption at any point can lead to metabolic diseases such as diabetes mellitus. Because "glucose-dependent insulin secretion" refers to an integrated cellular response involving multiple proteins and pathways—not a discrete druggable entity—it should not be listed as a canonical therapeutic target. Instead, individual components like *glucokinase*, *GLUT2*, *KATP channel subunits*, or *voltage-gated calcium channels* are considered true molecular targets for drug development[4][6]. If you need structured information on one of these specific molecules involved in this pathway—for example "Glucokinase," "ATP-sensitive potassium channel," or "GLUT2 transporter"—please specify which component you would like detailed information about.

Other names

Glucose-stimulated insulin secretion (GSIS)Glucose-dependent insulin releaseInsulin secretion in response to glucose